Aspergillosis IgM antibodies

Blood

Report in 120Hrs

At Home

No Fasting Required

Details

This test measures the presence of IgM antibodies against Aspergillus species, indicating a recent or acute immune response to Aspergillus infection

₹2,520₹3,215

22% OFF

Aspergillosis IgM Antibodies - Comprehensive Medical Test Guide

Why is it done?
- Detects early or acute Aspergillus infection through identification of IgM antibodies produced in the initial immune response to Aspergillus species
- Differentiates acute or recent Aspergillus infection from chronic or past infections by distinguishing IgM antibodies from IgG antibodies
- Ordered when patients present with respiratory symptoms (cough, dyspnea, hemoptysis) suspected to be caused by Aspergillus fumigatus or other Aspergillus species
- Performed in immunocompromised patients (HIV/AIDS, transplant recipients, chemotherapy patients) at risk for invasive aspergillosis
- Used to evaluate patients with allergic bronchopulmonary aspergillosis (ABPA) or aspergilloma (fungal ball)
- Typically ordered during the acute phase of infection when clinical suspicion is highest, usually within the first 2-4 weeks of symptom onset
Normal Range
- Negative Result: Less than 0.9 Index (or <0.90 depending on laboratory), indicating absence of IgM antibodies to Aspergillus
- Borderline/Equivocal Result: Index range 0.9 - 1.1, requiring repeat testing or additional confirmatory tests
- Positive Result: Greater than 1.1 Index (or >1.10), suggesting presence of IgM antibodies and possible acute Aspergillus infection
- Units of Measurement: Index values (unitless ratio), though some laboratories may report as optical density (OD) or percentage inhibition
- Normal/Negative: Indicates absence of detectable IgM response; may represent no current or recent Aspergillus exposure
- Abnormal/Positive: Indicates acute or recent Aspergillus infection requiring clinical correlation with symptoms and additional testing
Interpretation
- Positive IgM Result (>1.1 Index): Suggests acute or recent primary Aspergillus infection; indicates current active immune response; typically appears within first 1-2 weeks of infection and declines over 4-12 weeks
- Negative IgM Result (<0.9 Index): Indicates no detectable acute infection; may represent chronic infection, past exposure, or absence of infection; does not exclude Aspergillus disease if symptoms persist
- Borderline Result (0.9-1.1 Index): Requires careful clinical interpretation; repeat testing in 1-2 weeks may clarify; consider testing IgG antibodies for additional information
- Clinical Significance in Different Scenarios:
- ABPA (Allergic Bronchopulmonary Aspergillosis): Positive IgM with elevated IgE and IgG supports diagnosis; indicates ongoing immune sensitization
- Invasive Aspergillosis: Positive IgM in severely immunocompromised patients is significant; may indicate disseminated disease requiring immediate intervention
- Aspergilloma: Typically shows negative or low-positive IgM with positive IgG; chronic nature means IgM response is minimal
- Factors Affecting Results:
- Timing of blood collection relative to infection onset (peak IgM occurs 2-4 weeks after exposure)
- Immunocompetence of patient (severely immunocompromised patients may show weak or absent IgM response)
- Laboratory methodology and specific Aspergillus species involved (results may vary between A. fumigatus, A. niger, A. flavus)
- Previous Aspergillus exposure or vaccination history may affect antibody levels
Associated Organs
- Primary Organ Systems:
- Respiratory System: Lungs are primary site of Aspergillus infection following inhalation of fungal spores
- Immune System: Antibody production occurs in response to fungal antigen recognition
- Diseases Commonly Associated with Positive Results:
- Allergic Bronchopulmonary Aspergillosis (ABPA): Hypersensitivity reaction with IgE-mediated response; more common in asthmatic and cystic fibrosis patients
- Invasive Pulmonary Aspergillosis (IPA): Severe infection in immunocompromised patients; can rapidly progress to systemic disease
- Chronic Pulmonary Aspergillosis (CPA): Long-term colonization of lungs; includes aspergilloma and chronic cavitary pulmonary aspergillosis
- Aspergilloma (Fungal Ball): Colonization within cavitary lung disease (tuberculosis, sarcoidosis)
- Aspergillus Sinusitis: Infection of paranasal sinuses; may be fungal ball or invasive form
- Potential Complications Associated with Abnormal Results:
- Progressive Respiratory Compromise: Obstruction of airways, pulmonary hemorrhage, respiratory failure
- Systemic Dissemination: Hematogenous spread to brain, heart, kidneys, and other organs in severe cases
- Sepsis and Shock: Life-threatening systemic inflammation, particularly in immunocompromised patients
- Chronic Lung Fibrosis: Long-term scarring and reduced lung function from chronic aspergillosis
Follow-up Tests
- Recommended Follow-up Tests Based on Positive or Borderline Results:
- Aspergillosis IgG Antibodies: Indicates past or chronic infection; helps differentiate acute from chronic disease; IgG typically appears after IgM and persists longer
- Aspergillus-specific IgE and Total IgE: Essential for ABPA diagnosis; elevated IgE levels support hypersensitivity response
- High-Resolution CT Chest: Imaging to identify pulmonary involvement, cavitary disease, aspergilloma, or infiltrates consistent with aspergillosis
- Galactomannan Antigen Test: Detects Aspergillus antigen in serum; useful for invasive aspergillosis diagnosis in immunocompromised patients
- Aspergillus PCR (Polymerase Chain Reaction): Molecular detection of Aspergillus DNA; higher sensitivity and faster results than culture
- Sputum Culture and Microscopy: Direct fungal culture to identify Aspergillus species and assess fungal load
- Bronchoalveolar Lavage (BAL): Collection of respiratory secretions for culture, PCR, and galactomannan testing; provides direct sampling of infected lung tissue
- Fungal Culture from Blood: Indicated for suspected invasive aspergillosis in immunocompromised patients
- Pulmonary Function Tests (PFT): Assess lung function and measure degree of compromise; baseline and follow-up measurements
- Chest X-Ray: Initial screening for pulmonary abnormalities, though HRCT provides superior detail
- Monitoring Frequency for Ongoing Conditions:
- ABPA Monitoring: IgE and IgG antibodies every 3-6 months during active disease; more frequently if symptoms change
- Invasive Aspergillosis: Serial galactomannan and PCR testing at least weekly in high-risk patients; daily monitoring in critically ill
- Chronic Pulmonary Aspergillosis: Annual HRCT imaging; IgG antibody levels annually to monitor disease burden
- Post-Treatment: Repeat IgM and IgG testing 4-8 weeks after treatment completion to assess immune response
Fasting Required?
- Fasting Required: No
- Fasting is not necessary for Aspergillosis IgM antibody testing as this is a serological blood test unaffected by food or fluid intake
- Patient Preparation Requirements:
- Standard venipuncture: Patient should have arm accessible; comfortable position sitting or lying down is recommended
- Timing: No specific time of day required; testing can be performed at any time convenient for the patient
- Hydration: Adequate hydration is beneficial to facilitate blood draw but not mandatory
- Medications: No specific medications need to be avoided; continue all regular medications unless otherwise instructed by physician
- Immunosuppressive medications and systemic corticosteroids will not affect antibody test validity; inform laboratory if patient is on chemotherapy or immunosuppressive therapy
- Additional Preparation Notes:
- Blood collection requires approximately 3-5 mL of serum in a standard SST (serum separator tube) or equivalent collection tube
- Allow blood to clot at room temperature for 15-30 minutes before centrifugation per laboratory protocol
- Separate serum within 1-2 hours of collection to ensure sample quality and prevent hemolysis
- Serum may be refrigerated at 2-8°C for up to 14 days or frozen at -20°C for extended storage pending test analysis

How our test process works!